Albert Bourla, DVM, PhD
“It will take not only science but also an unwavering commitment to reducing healthcare disparities so that all people can benefit from that science.”
Albert Bourla is the CEO and Chairman of Pfizer, one of the world’s premier innovative biopharmaceutical companies.
Prior to becoming CEO, Bourla served as the Chief Operating Officer, overseeing the company’s commercial, strategy, manufacturing, and global product development. As the former Group President of Pfizer Innovative Health, he was responsible for the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, and Vaccines business groups, as well as for creating the Patient and Health Impact group that focused on developing solutions for increasing patient access and ensuring broader business model innovation. Bourla’s other roles include Group President of Global Vaccines, Oncology, and Consumer Healthcare Business; President and General Manager of Established Products; and Area President of Pfizer Animal Health in Europe, Africa, Middle East, and Asia-Pacific regions.
Bourla currently serves on the Board of the Pfizer Foundation, which promotes access to quality health care, and the Executive Committee of Biotechnology Innovation Organization (BIO), the world’s largest biotechnology trade association.
Bourla is a Doctor of Veterinary Medicine and holds a Ph.D. in the biotechnology of reproduction from the Veterinary School of Aristotle University. Prior to joining Pfizer in the animal health division, he was a practicing veterinarian in Greece.